Mutual of America Capital Management LLC Sells 6,506 Shares of Johnson & Johnson (NYSE:JNJ)

Mutual of America Capital Management LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJFree Report) by 1.9% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 327,897 shares of the company’s stock after selling 6,506 shares during the quarter. Johnson & Johnson comprises 0.6% of Mutual of America Capital Management LLC’s portfolio, making the stock its 21st biggest holding. Mutual of America Capital Management LLC’s holdings in Johnson & Johnson were worth $51,870,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Christopher J. Hasenberg Inc acquired a new stake in Johnson & Johnson during the 1st quarter worth $31,000. Keener Financial Planning LLC bought a new position in Johnson & Johnson during the fourth quarter worth about $40,000. WFA Asset Management Corp increased its stake in shares of Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after acquiring an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $44,000. Finally, Disciplined Equity Management Inc. bought a new position in Johnson & Johnson during the 4th quarter worth approximately $45,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 1.1 %

JNJ stock opened at $147.05 on Wednesday. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97. The company has a market cap of $353.90 billion, a price-to-earnings ratio of 9.17, a P/E/G ratio of 2.42 and a beta of 0.52. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The business has a 50 day moving average price of $147.96 and a two-hundred day moving average price of $153.59.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm’s revenue was up 2.3% on a year-over-year basis. During the same period last year, the business earned $2.68 earnings per share. Analysts anticipate that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.37%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Analyst Ratings Changes

Several equities research analysts have weighed in on JNJ shares. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday, June 30th. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a research report on Monday, June 17th. Morgan Stanley cut their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. Finally, Bank of America dropped their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Eight investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.07.

Get Our Latest Stock Analysis on Johnson & Johnson

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.